You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Water-soluble salt of lamotrigine (Cat. No. 1611). Displays anticonvulsant effects and inhibits glutamate release, possibly through inhibition of Na+, K+ and Ca2+ currents.
Sold for research purposes under agreement from GlaxoSmithKline
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||38.22||100 with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 382.22. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.62 mL||13.08 mL||26.16 mL|
|5 mM||0.52 mL||2.62 mL||5.23 mL|
|10 mM||0.26 mL||1.31 mL||2.62 mL|
|50 mM||0.05 mL||0.26 mL||0.52 mL|
References are publications that support the biological activity of the product.
Leach et al (1991) Neurochemical and behavioral aspects of lamotr. Epilepsia 32 S4 PMID: 1685439
Smith and Meldrum (1995) Cardioprotective effect of lamotr. after focal ischemia in rats. Stroke 26 117 PMID: 7839380
Zona and Avoli (1997) Lamotrigine reduces voltage-gated sodium currents in rat central neurons in culture. Epilepsia 38 522 PMID: 9184596
Grunze et al (1998) Modulation of calcium and potassium currents by lamotr. Neuropsychobiology 38 131 PMID: 9778600
If you know of a relevant reference for Lamotrigine isethionate, please let us know.
View Related Products by Target
Keywords: Lamotrigine isethionate, Lamotrigine isethionate supplier, inhibitors, inhibits, glutamate, release, Receptors, GlaxoSmithKline, GSK, Miscellaneous, Glutamate, Other, Channel, Modulators, 2289, Tocris Bioscience
1 Citation for Lamotrigine isethionate
Citations are publications that use Tocris products. Selected citations for Lamotrigine isethionate include:
Madry et al (2018) Microglial Ramification, Surveillance, and Interleukin-1β Release Are Regulated by the Two-Pore Domain K+ Channel THIK-1. Neuron 97 299 PMID: 29290552
Do you know of a great paper that uses Lamotrigine isethionate from Tocris? Please let us know.
Reviews for Lamotrigine isethionate
There are currently no reviews for this product. Be the first to review Lamotrigine isethionate and earn rewards!
Have you used Lamotrigine isethionate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.